Get the Stockscreener App
5.59
34.87%
1.46
After Hours:
5.58
-0.010
-0.18%
Evolus Inc stock is traded at $5.59, with a volume of 10.31M.
It is up +34.87% in the last 24 hours and up +21.35% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$4.13
Open:
$5.37
24h Volume:
10.31M
Relative Volume:
8.97
Market Cap:
$362.34M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-5.1759
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+23.78%
1M Performance:
+21.35%
6M Performance:
-25.83%
1Y Performance:
-61.18%
1-Day Range:
$5.065
$6.13
1-Week Range:
$4.10
$6.13
52-Week Range:
$4.0913
$14.60
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.59 | 267.71M | 202.09M | -61.69M | -35.64M | -1.08 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
Evolus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Evolus Q4 2025 slides: revenue growth continues despite forecast miss By Investing.com - Investing.com Canada
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Aug Sectors: What analysts say about Evolus Inc stockTrade Risk Assessment & AI Enhanced Trading Alerts - baoquankhu1.vn
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips - Investing.com
Evolus Q4 Earnings Call Highlights - MarketBeat
Evolus Shares Up 17% on Q4, Full Year Earnings - Orange County Business Journal
Evolus, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-03-03 - Seeking Alpha
Evolus (EOLS) Q4 2025 Earnings Call Transcript - AOL.com
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Yahoo Finance
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans - Stock Titan
EOLS Projects Strong Financial Growth Through 2028 - GuruFocus
Evolus : Investor Presentation - marketscreener.com
Evolus Incenters loan and security agreement with Eclipse Business Capital on March 3, 2026SEC filing - marketscreener.com
EOLS Reports Strong Q4 Revenue Surpassing Expectations - GuruFocus
Evolus Posts Q4 Breakeven Results, Revenue Rises; Shares Gain After Hours - marketscreener.com
Evolus 2025 10-K: $297.2M Revenue, $(0.80) EPS - TradingView
Evolus Secures New Credit Facility and Reports Profitability - TipRanks
Evolus Q4 Earnings Summary & Key Takeaways - Benzinga
Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Evolus (NASDAQ: EOLS) wins $30M credit line and 12% 2025 sales rise - Stock Titan
Evolus, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
EOLS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Evolus recently officially disclosed its financial results for the fourth quarter and full year of 2025. - Bitget
Evolus Shares Earn 'Moderate Buy' Rating from Analysts - National Today
What to Expect from Evolus's Earnings - Benzinga
Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: A 237% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Evolus to join Leerink Partners Healthcare Conference for fireside chat and strategy talks - Traders Union
Evolus to Participate in The Leerink Partners Global Healthcare Conference - ChartMill
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Evolus (EOLS) Expected to Announce Earnings on Tuesday - MarketBeat
Aug Highlights: How volatile is CTEV stockTrend Reversal & High Accuracy Investment Entry Signals - baoquankhu1.vn
Evolus, Inc. (EOLS) Stock Analysis: A Potential 243% Upside Ignites Investor Interest - DirectorsTalk Interviews
Evolus (EOLS) awards RSUs and stock options to officer Rui Avelar - Stock Titan
Evolus (NASDAQ: EOLS) grants RSUs, PSUs and options to executive David Moatazedi - Stock Titan
How sustainable is Evolus Inc. stock dividend payoutWeekly Stock Recap & Intraday High Probability Setup Alerts - mfd.ru
Director at Evolus (EOLS) receives 45,559 restricted stock units in equity grant - Stock Titan
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead - Intellectia AI
Caligan exits Evolus (EOLS), amended filing shows 0% ownership - Stock Titan
Major holder Timothy P. Lynch reports 9.9% stake in Evolus (EOLS) - Stock Titan
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 - BioSpace
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - MSN
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 13, 2026 - BioSpace
How Evolus Inc. stock compares to growth peers2025 Volume Leaders & High Yield Equity Trading Tips - mfd.ru
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
1.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):